Moreover, targeting ICIs with phagocytosis checkpoints such as the CD47-SIRPα axis as well as epigenetic checkpoints like REGNASE-1, PAC-1, or PI3K-AGK pathways which are upregulated in some cancer cells may build up a strong connection between innate and adaptive immune cells to provide a more successful way for the treatments of cancer patients rather than conventional therapeutic approaches. The gene discussed is SIRPA; the disease is cancer.